Results 101 to 110 of about 204,987 (288)
FEBS Open Bio, EarlyView.We first identified functional murine mitochondrial N‐formyl peptides (MT‐FPs) and investigated their effects on the in vitro myeloid‐derived suppressor cell (MDSC) generation from bone marrow cells. We demonstrated that MT‐FPs acted directly on bone marrow cells to promote MDSC generation and modulated the polymorphonuclear (PMN)‐MDSC/monocyte (M ...
Miyako Ozawa +2 more
wiley +1 more source
Development of human monoclonal antibodies against TARM1 by yeast display
FEBS Open Bio, EarlyView.Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe +5 more
wiley +1 more source
Targeting STAT3 in Cancer with Nucleotide Therapeutics. [PDF]
, 2019 Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an "undruggable" target for ...
Grandis, Jennifer R +3 more
core +2 more sources
Digital twins to accelerate target identification and drug development for immune‐mediated disorders
FEBS Open Bio, EarlyView.Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley +1 more source
Tumour-immune dynamics with an immune checkpoint inhibitor
Letters in Biomathematics, 2018 The use of immune checkpoint inhibitors is becoming more commonplace in clinical trials across the nation. Two important factors in the tumour-immune response are the checkpoint protein programmed death-1 (PD-1) and its ligand PD-L1.
Elpiniki Nikolopoulou +5 more
doaj +1 more source
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. [PDF]
, 2017 Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter
Barnett, Stephen A +10 more
core +2 more sources
FEBS Open Bio, EarlyView.Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero +5 more
wiley +1 more source
Anti–PD-1-induced bullous pemphigoid in a renal transplant recipient
SAGE Open Medical Case ReportsImmune checkpoint inhibitors, particularly anti–PD-1 agents, are increasingly associated with bullous pemphigoid, a rare yet significant immune-related adverse event. We report a case of immune checkpoint inhibitor-induced bullous pemphigoid in a 74-year-
Ghassan Barnawi +5 more
doaj +1 more source
Immune checkpoint inhibitor-related endocrinopathies
Journal of Translational Internal Medicine, 2022 Lu, Difei, Gao, Ying
openaire +2 more sources
The role of the immune system in brain metastasis [PDF]
, 2019 Metastatic brain tumors are the most common brain tumors in adults. With numerous successful advancements in systemic treatment of most common cancer types, brain metastasis is becoming increasingly important in the overall prognosis of cancer patients ...
Dey, Mahua +2 more
core